nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—Risedronate—osteoporosis	0.173	0.325	CbGbCtD
Sulindac—ALB—Estropipate—osteoporosis	0.0826	0.155	CbGbCtD
Sulindac—CYP1A1—Cholecalciferol—osteoporosis	0.0569	0.107	CbGbCtD
Sulindac—CYP1A2—Estropipate—osteoporosis	0.0494	0.0929	CbGbCtD
Sulindac—CYP1A1—Estradiol—osteoporosis	0.0459	0.0864	CbGbCtD
Sulindac—SLC22A6—Conjugated Estrogens—osteoporosis	0.0458	0.0863	CbGbCtD
Sulindac—ALB—Estradiol—osteoporosis	0.0343	0.0645	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—osteoporosis	0.0334	0.499	CbGeAlD
Sulindac—CYP1A2—Conjugated Estrogens—osteoporosis	0.0234	0.0439	CbGbCtD
Sulindac—CYP1A2—Estradiol—osteoporosis	0.0205	0.0386	CbGbCtD
Sulindac—MAPK3—periosteum—osteoporosis	0.0167	0.25	CbGeAlD
Sulindac—PTGS2—periosteum—osteoporosis	0.00434	0.0649	CbGeAlD
Sulindac—AKR1B1—uterus—osteoporosis	0.00315	0.0471	CbGeAlD
Sulindac—AKR1B1—bone marrow—osteoporosis	0.00267	0.04	CbGeAlD
Sulindac—MAPK3—uterus—osteoporosis	0.00228	0.0341	CbGeAlD
Sulindac—MAPK3—bone marrow—osteoporosis	0.00194	0.029	CbGeAlD
Sulindac—CYP1A1—uterus—osteoporosis	0.000707	0.0106	CbGeAlD
Sulindac—PTGS1—uterus—osteoporosis	0.000621	0.00928	CbGeAlD
Sulindac—PTGS2—uterus—osteoporosis	0.000593	0.00887	CbGeAlD
Sulindac—PTGS2—bone marrow—osteoporosis	0.000504	0.00753	CbGeAlD
Sulindac—Vertigo—Zoledronate—osteoporosis	0.000263	0.00122	CcSEcCtD
Sulindac—Syncope—Zoledronate—osteoporosis	0.000263	0.00122	CcSEcCtD
Sulindac—Leukopenia—Zoledronate—osteoporosis	0.000262	0.00122	CcSEcCtD
Sulindac—Oedema—Pamidronate—osteoporosis	0.000262	0.00121	CcSEcCtD
Sulindac—Anaphylactic shock—Pamidronate—osteoporosis	0.000262	0.00121	CcSEcCtD
Sulindac—Urticaria—Calcitriol—osteoporosis	0.00026	0.0012	CcSEcCtD
Sulindac—Hepatitis—Estradiol—osteoporosis	0.00026	0.0012	CcSEcCtD
Sulindac—Palpitations—Zoledronate—osteoporosis	0.000259	0.0012	CcSEcCtD
Sulindac—Body temperature increased—Calcitriol—osteoporosis	0.000259	0.0012	CcSEcCtD
Sulindac—Angioedema—Conjugated Estrogens—osteoporosis	0.000258	0.0012	CcSEcCtD
Sulindac—Shock—Pamidronate—osteoporosis	0.000258	0.00119	CcSEcCtD
Sulindac—Loss of consciousness—Zoledronate—osteoporosis	0.000258	0.00119	CcSEcCtD
Sulindac—Hypersensitivity—Estropipate—osteoporosis	0.000257	0.00119	CcSEcCtD
Sulindac—Thrombocytopenia—Pamidronate—osteoporosis	0.000257	0.00119	CcSEcCtD
Sulindac—Vomiting—Etidronic acid—osteoporosis	0.000256	0.00119	CcSEcCtD
Sulindac—Tachycardia—Pamidronate—osteoporosis	0.000256	0.00118	CcSEcCtD
Sulindac—Rash—Etidronic acid—osteoporosis	0.000254	0.00118	CcSEcCtD
Sulindac—Convulsion—Zoledronate—osteoporosis	0.000254	0.00118	CcSEcCtD
Sulindac—Dermatitis—Etidronic acid—osteoporosis	0.000254	0.00118	CcSEcCtD
Sulindac—Vertigo—Conjugated Estrogens—osteoporosis	0.000254	0.00118	CcSEcCtD
Sulindac—Hyperhidrosis—Pamidronate—osteoporosis	0.000253	0.00117	CcSEcCtD
Sulindac—Syncope—Conjugated Estrogens—osteoporosis	0.000253	0.00117	CcSEcCtD
Sulindac—Hypertension—Zoledronate—osteoporosis	0.000253	0.00117	CcSEcCtD
Sulindac—Hypersensitivity—Alendronate—osteoporosis	0.000253	0.00117	CcSEcCtD
Sulindac—Headache—Etidronic acid—osteoporosis	0.000253	0.00117	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000251	0.00116	CcSEcCtD
Sulindac—Asthenia—Estropipate—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Visual impairment—Estradiol—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Anorexia—Pamidronate—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Myalgia—Zoledronate—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Arthralgia—Zoledronate—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Chest pain—Zoledronate—osteoporosis	0.00025	0.00116	CcSEcCtD
Sulindac—Palpitations—Conjugated Estrogens—osteoporosis	0.000249	0.00116	CcSEcCtD
Sulindac—Insomnia—Risedronate—osteoporosis	0.000249	0.00115	CcSEcCtD
Sulindac—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000248	0.00115	CcSEcCtD
Sulindac—Paraesthesia—Risedronate—osteoporosis	0.000247	0.00115	CcSEcCtD
Sulindac—Pruritus—Estropipate—osteoporosis	0.000247	0.00114	CcSEcCtD
Sulindac—Discomfort—Zoledronate—osteoporosis	0.000247	0.00114	CcSEcCtD
Sulindac—Asthenia—Alendronate—osteoporosis	0.000246	0.00114	CcSEcCtD
Sulindac—Hypersensitivity—Ibandronate—osteoporosis	0.000246	0.00114	CcSEcCtD
Sulindac—Dyspnoea—Risedronate—osteoporosis	0.000246	0.00114	CcSEcCtD
Sulindac—Erythema multiforme—Estradiol—osteoporosis	0.000245	0.00114	CcSEcCtD
Sulindac—Hypotension—Pamidronate—osteoporosis	0.000245	0.00113	CcSEcCtD
Sulindac—Convulsion—Conjugated Estrogens—osteoporosis	0.000245	0.00113	CcSEcCtD
Sulindac—Fatigue—Ethinyl Estradiol—osteoporosis	0.000244	0.00113	CcSEcCtD
Sulindac—Pruritus—Alendronate—osteoporosis	0.000243	0.00113	CcSEcCtD
Sulindac—Dyspepsia—Risedronate—osteoporosis	0.000243	0.00112	CcSEcCtD
Sulindac—Tinnitus—Estradiol—osteoporosis	0.000242	0.00112	CcSEcCtD
Sulindac—Constipation—Ethinyl Estradiol—osteoporosis	0.000242	0.00112	CcSEcCtD
Sulindac—Hypersensitivity—Calcitriol—osteoporosis	0.000241	0.00112	CcSEcCtD
Sulindac—Flushing—Estradiol—osteoporosis	0.000241	0.00112	CcSEcCtD
Sulindac—Myalgia—Conjugated Estrogens—osteoporosis	0.00024	0.00111	CcSEcCtD
Sulindac—Arthralgia—Conjugated Estrogens—osteoporosis	0.00024	0.00111	CcSEcCtD
Sulindac—Chest pain—Conjugated Estrogens—osteoporosis	0.00024	0.00111	CcSEcCtD
Sulindac—Asthenia—Ibandronate—osteoporosis	0.00024	0.00111	CcSEcCtD
Sulindac—Nausea—Etidronic acid—osteoporosis	0.000239	0.00111	CcSEcCtD
Sulindac—Oedema—Zoledronate—osteoporosis	0.000239	0.00111	CcSEcCtD
Sulindac—Anaphylactic shock—Zoledronate—osteoporosis	0.000239	0.00111	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000239	0.00111	CcSEcCtD
Sulindac—Diarrhoea—Estropipate—osteoporosis	0.000239	0.00111	CcSEcCtD
Sulindac—Fatigue—Risedronate—osteoporosis	0.000238	0.0011	CcSEcCtD
Sulindac—Insomnia—Pamidronate—osteoporosis	0.000237	0.0011	CcSEcCtD
Sulindac—Pruritus—Ibandronate—osteoporosis	0.000237	0.0011	CcSEcCtD
Sulindac—Constipation—Risedronate—osteoporosis	0.000236	0.00109	CcSEcCtD
Sulindac—Shock—Zoledronate—osteoporosis	0.000235	0.00109	CcSEcCtD
Sulindac—Paraesthesia—Pamidronate—osteoporosis	0.000235	0.00109	CcSEcCtD
Sulindac—Diarrhoea—Alendronate—osteoporosis	0.000235	0.00109	CcSEcCtD
Sulindac—Asthenia—Calcitriol—osteoporosis	0.000235	0.00109	CcSEcCtD
Sulindac—Thrombocytopenia—Zoledronate—osteoporosis	0.000234	0.00109	CcSEcCtD
Sulindac—Dyspnoea—Pamidronate—osteoporosis	0.000234	0.00108	CcSEcCtD
Sulindac—Tachycardia—Zoledronate—osteoporosis	0.000234	0.00108	CcSEcCtD
Sulindac—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000233	0.00108	CcSEcCtD
Sulindac—Chills—Estradiol—osteoporosis	0.000233	0.00108	CcSEcCtD
Sulindac—Somnolence—Pamidronate—osteoporosis	0.000233	0.00108	CcSEcCtD
Sulindac—Pruritus—Calcitriol—osteoporosis	0.000232	0.00107	CcSEcCtD
Sulindac—Hyperhidrosis—Zoledronate—osteoporosis	0.000231	0.00107	CcSEcCtD
Sulindac—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000231	0.00107	CcSEcCtD
Sulindac—Diarrhoea—Raloxifene—osteoporosis	0.000231	0.00107	CcSEcCtD
Sulindac—Dyspepsia—Pamidronate—osteoporosis	0.000231	0.00107	CcSEcCtD
Sulindac—Dizziness—Estropipate—osteoporosis	0.000231	0.00107	CcSEcCtD
Sulindac—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00023	0.00107	CcSEcCtD
Sulindac—Oedema—Conjugated Estrogens—osteoporosis	0.00023	0.00107	CcSEcCtD
Sulindac—Alopecia—Estradiol—osteoporosis	0.000229	0.00106	CcSEcCtD
Sulindac—Diarrhoea—Ibandronate—osteoporosis	0.000229	0.00106	CcSEcCtD
Sulindac—Anorexia—Zoledronate—osteoporosis	0.000228	0.00106	CcSEcCtD
Sulindac—Decreased appetite—Pamidronate—osteoporosis	0.000228	0.00106	CcSEcCtD
Sulindac—Dizziness—Alendronate—osteoporosis	0.000227	0.00105	CcSEcCtD
Sulindac—Shock—Conjugated Estrogens—osteoporosis	0.000227	0.00105	CcSEcCtD
Sulindac—Fatigue—Pamidronate—osteoporosis	0.000226	0.00105	CcSEcCtD
Sulindac—Gastrointestinal pain—Risedronate—osteoporosis	0.000225	0.00104	CcSEcCtD
Sulindac—Tachycardia—Conjugated Estrogens—osteoporosis	0.000225	0.00104	CcSEcCtD
Sulindac—Urticaria—Ethinyl Estradiol—osteoporosis	0.000225	0.00104	CcSEcCtD
Sulindac—Constipation—Pamidronate—osteoporosis	0.000224	0.00104	CcSEcCtD
Sulindac—Diarrhoea—Calcitriol—osteoporosis	0.000224	0.00104	CcSEcCtD
Sulindac—Hypotension—Zoledronate—osteoporosis	0.000224	0.00104	CcSEcCtD
Sulindac—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000223	0.00104	CcSEcCtD
Sulindac—Dizziness—Raloxifene—osteoporosis	0.000223	0.00103	CcSEcCtD
Sulindac—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000223	0.00103	CcSEcCtD
Sulindac—Flatulence—Estradiol—osteoporosis	0.000223	0.00103	CcSEcCtD
Sulindac—Tension—Estradiol—osteoporosis	0.000222	0.00103	CcSEcCtD
Sulindac—Vomiting—Estropipate—osteoporosis	0.000222	0.00103	CcSEcCtD
Sulindac—Dysgeusia—Estradiol—osteoporosis	0.000221	0.00103	CcSEcCtD
Sulindac—Dizziness—Ibandronate—osteoporosis	0.000221	0.00102	CcSEcCtD
Sulindac—Rash—Estropipate—osteoporosis	0.00022	0.00102	CcSEcCtD
Sulindac—Dermatitis—Estropipate—osteoporosis	0.00022	0.00102	CcSEcCtD
Sulindac—Anorexia—Conjugated Estrogens—osteoporosis	0.00022	0.00102	CcSEcCtD
Sulindac—Nervousness—Estradiol—osteoporosis	0.000219	0.00102	CcSEcCtD
Sulindac—Urticaria—Risedronate—osteoporosis	0.000219	0.00101	CcSEcCtD
Sulindac—Headache—Estropipate—osteoporosis	0.000218	0.00101	CcSEcCtD
Sulindac—Vomiting—Alendronate—osteoporosis	0.000218	0.00101	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000218	0.00101	CcSEcCtD
Sulindac—Body temperature increased—Risedronate—osteoporosis	0.000218	0.00101	CcSEcCtD
Sulindac—Rash—Alendronate—osteoporosis	0.000217	0.001	CcSEcCtD
Sulindac—Insomnia—Zoledronate—osteoporosis	0.000216	0.001	CcSEcCtD
Sulindac—Dermatitis—Alendronate—osteoporosis	0.000216	0.001	CcSEcCtD
Sulindac—Feeling abnormal—Pamidronate—osteoporosis	0.000216	0.001	CcSEcCtD
Sulindac—Hypotension—Conjugated Estrogens—osteoporosis	0.000215	0.000997	CcSEcCtD
Sulindac—Headache—Alendronate—osteoporosis	0.000215	0.000997	CcSEcCtD
Sulindac—Paraesthesia—Zoledronate—osteoporosis	0.000215	0.000995	CcSEcCtD
Sulindac—Vomiting—Raloxifene—osteoporosis	0.000215	0.000995	CcSEcCtD
Sulindac—Gastrointestinal pain—Pamidronate—osteoporosis	0.000214	0.000992	CcSEcCtD
Sulindac—Dyspnoea—Zoledronate—osteoporosis	0.000213	0.000988	CcSEcCtD
Sulindac—Rash—Raloxifene—osteoporosis	0.000213	0.000987	CcSEcCtD
Sulindac—Dermatitis—Raloxifene—osteoporosis	0.000213	0.000986	CcSEcCtD
Sulindac—Somnolence—Zoledronate—osteoporosis	0.000213	0.000986	CcSEcCtD
Sulindac—Vomiting—Ibandronate—osteoporosis	0.000213	0.000985	CcSEcCtD
Sulindac—Headache—Raloxifene—osteoporosis	0.000212	0.00098	CcSEcCtD
Sulindac—Rash—Ibandronate—osteoporosis	0.000211	0.000977	CcSEcCtD
Sulindac—Dermatitis—Ibandronate—osteoporosis	0.000211	0.000976	CcSEcCtD
Sulindac—Dyspepsia—Zoledronate—osteoporosis	0.000211	0.000976	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00021	0.000973	CcSEcCtD
Sulindac—Ill-defined disorder—Estradiol—osteoporosis	0.00021	0.000971	CcSEcCtD
Sulindac—Headache—Ibandronate—osteoporosis	0.000209	0.000971	CcSEcCtD
Sulindac—Insomnia—Conjugated Estrogens—osteoporosis	0.000208	0.000965	CcSEcCtD
Sulindac—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000208	0.000965	CcSEcCtD
Sulindac—Vomiting—Calcitriol—osteoporosis	0.000208	0.000964	CcSEcCtD
Sulindac—Decreased appetite—Zoledronate—osteoporosis	0.000208	0.000964	CcSEcCtD
Sulindac—Nausea—Estropipate—osteoporosis	0.000207	0.00096	CcSEcCtD
Sulindac—Body temperature increased—Pamidronate—osteoporosis	0.000207	0.000959	CcSEcCtD
Sulindac—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000207	0.000959	CcSEcCtD
Sulindac—Angioedema—Estradiol—osteoporosis	0.000206	0.000957	CcSEcCtD
Sulindac—Rash—Calcitriol—osteoporosis	0.000206	0.000956	CcSEcCtD
Sulindac—Fatigue—Zoledronate—osteoporosis	0.000206	0.000956	CcSEcCtD
Sulindac—Dermatitis—Calcitriol—osteoporosis	0.000206	0.000955	CcSEcCtD
Sulindac—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000205	0.000952	CcSEcCtD
Sulindac—Headache—Calcitriol—osteoporosis	0.000205	0.00095	CcSEcCtD
Sulindac—Somnolence—Conjugated Estrogens—osteoporosis	0.000205	0.000949	CcSEcCtD
Sulindac—Constipation—Zoledronate—osteoporosis	0.000205	0.000948	CcSEcCtD
Sulindac—Nausea—Alendronate—osteoporosis	0.000204	0.000945	CcSEcCtD
Sulindac—Malaise—Estradiol—osteoporosis	0.000204	0.000944	CcSEcCtD
Sulindac—Hypersensitivity—Risedronate—osteoporosis	0.000203	0.000941	CcSEcCtD
Sulindac—Vertigo—Estradiol—osteoporosis	0.000203	0.00094	CcSEcCtD
Sulindac—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000203	0.00094	CcSEcCtD
Sulindac—Asthenia—Ethinyl Estradiol—osteoporosis	0.000203	0.00094	CcSEcCtD
Sulindac—Syncope—Estradiol—osteoporosis	0.000203	0.000939	CcSEcCtD
Sulindac—Nausea—Raloxifene—osteoporosis	0.000201	0.00093	CcSEcCtD
Sulindac—Decreased appetite—Conjugated Estrogens—osteoporosis	0.0002	0.000928	CcSEcCtD
Sulindac—Pruritus—Ethinyl Estradiol—osteoporosis	0.0002	0.000926	CcSEcCtD
Sulindac—Palpitations—Estradiol—osteoporosis	0.0002	0.000925	CcSEcCtD
Sulindac—Fatigue—Conjugated Estrogens—osteoporosis	0.000199	0.00092	CcSEcCtD
Sulindac—Nausea—Ibandronate—osteoporosis	0.000199	0.00092	CcSEcCtD
Sulindac—Loss of consciousness—Estradiol—osteoporosis	0.000199	0.00092	CcSEcCtD
Sulindac—Asthenia—Risedronate—osteoporosis	0.000198	0.000916	CcSEcCtD
Sulindac—Feeling abnormal—Zoledronate—osteoporosis	0.000197	0.000914	CcSEcCtD
Sulindac—Constipation—Conjugated Estrogens—osteoporosis	0.000197	0.000913	CcSEcCtD
Sulindac—Gastrointestinal pain—Zoledronate—osteoporosis	0.000196	0.000907	CcSEcCtD
Sulindac—Hypertension—Estradiol—osteoporosis	0.000195	0.000904	CcSEcCtD
Sulindac—Pruritus—Risedronate—osteoporosis	0.000195	0.000903	CcSEcCtD
Sulindac—Nausea—Calcitriol—osteoporosis	0.000194	0.000901	CcSEcCtD
Sulindac—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000193	0.000896	CcSEcCtD
Sulindac—Hypersensitivity—Pamidronate—osteoporosis	0.000193	0.000894	CcSEcCtD
Sulindac—Myalgia—Estradiol—osteoporosis	0.000192	0.000891	CcSEcCtD
Sulindac—Arthralgia—Estradiol—osteoporosis	0.000192	0.000891	CcSEcCtD
Sulindac—Chest pain—Estradiol—osteoporosis	0.000192	0.000891	CcSEcCtD
Sulindac—Urticaria—Zoledronate—osteoporosis	0.00019	0.000881	CcSEcCtD
Sulindac—Discomfort—Estradiol—osteoporosis	0.00019	0.000881	CcSEcCtD
Sulindac—Body temperature increased—Zoledronate—osteoporosis	0.000189	0.000876	CcSEcCtD
Sulindac—Diarrhoea—Risedronate—osteoporosis	0.000189	0.000874	CcSEcCtD
Sulindac—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000188	0.000873	CcSEcCtD
Sulindac—Asthenia—Pamidronate—osteoporosis	0.000188	0.000871	CcSEcCtD
Sulindac—Dizziness—Ethinyl Estradiol—osteoporosis	0.000187	0.000866	CcSEcCtD
Sulindac—Pruritus—Pamidronate—osteoporosis	0.000185	0.000859	CcSEcCtD
Sulindac—Anaphylactic shock—Estradiol—osteoporosis	0.000184	0.000854	CcSEcCtD
Sulindac—Oedema—Estradiol—osteoporosis	0.000184	0.000854	CcSEcCtD
Sulindac—Urticaria—Conjugated Estrogens—osteoporosis	0.000183	0.000848	CcSEcCtD
Sulindac—Dizziness—Risedronate—osteoporosis	0.000182	0.000844	CcSEcCtD
Sulindac—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000182	0.000844	CcSEcCtD
Sulindac—Shock—Estradiol—osteoporosis	0.000181	0.000841	CcSEcCtD
Sulindac—Tachycardia—Estradiol—osteoporosis	0.00018	0.000834	CcSEcCtD
Sulindac—Vomiting—Ethinyl Estradiol—osteoporosis	0.00018	0.000833	CcSEcCtD
Sulindac—Diarrhoea—Pamidronate—osteoporosis	0.000179	0.00083	CcSEcCtD
Sulindac—Hyperhidrosis—Estradiol—osteoporosis	0.000178	0.000826	CcSEcCtD
Sulindac—Rash—Ethinyl Estradiol—osteoporosis	0.000178	0.000826	CcSEcCtD
Sulindac—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000178	0.000825	CcSEcCtD
Sulindac—Headache—Ethinyl Estradiol—osteoporosis	0.000177	0.00082	CcSEcCtD
Sulindac—Hypersensitivity—Zoledronate—osteoporosis	0.000176	0.000817	CcSEcCtD
Sulindac—Vomiting—Risedronate—osteoporosis	0.000175	0.000812	CcSEcCtD
Sulindac—Rash—Risedronate—osteoporosis	0.000174	0.000805	CcSEcCtD
Sulindac—Dermatitis—Risedronate—osteoporosis	0.000174	0.000804	CcSEcCtD
Sulindac—Dizziness—Pamidronate—osteoporosis	0.000173	0.000803	CcSEcCtD
Sulindac—Headache—Risedronate—osteoporosis	0.000173	0.0008	CcSEcCtD
Sulindac—Asthenia—Zoledronate—osteoporosis	0.000172	0.000795	CcSEcCtD
Sulindac—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00017	0.000786	CcSEcCtD
Sulindac—Pruritus—Zoledronate—osteoporosis	0.000169	0.000784	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000168	0.000778	CcSEcCtD
Sulindac—Nausea—Ethinyl Estradiol—osteoporosis	0.000168	0.000778	CcSEcCtD
Sulindac—Insomnia—Estradiol—osteoporosis	0.000167	0.000773	CcSEcCtD
Sulindac—Vomiting—Pamidronate—osteoporosis	0.000167	0.000772	CcSEcCtD
Sulindac—Paraesthesia—Estradiol—osteoporosis	0.000166	0.000767	CcSEcCtD
Sulindac—Asthenia—Conjugated Estrogens—osteoporosis	0.000165	0.000766	CcSEcCtD
Sulindac—Rash—Pamidronate—osteoporosis	0.000165	0.000765	CcSEcCtD
Sulindac—Dermatitis—Pamidronate—osteoporosis	0.000165	0.000765	CcSEcCtD
Sulindac—Dyspnoea—Estradiol—osteoporosis	0.000164	0.000762	CcSEcCtD
Sulindac—Headache—Pamidronate—osteoporosis	0.000164	0.00076	CcSEcCtD
Sulindac—Somnolence—Estradiol—osteoporosis	0.000164	0.00076	CcSEcCtD
Sulindac—Diarrhoea—Zoledronate—osteoporosis	0.000164	0.000759	CcSEcCtD
Sulindac—Nausea—Risedronate—osteoporosis	0.000164	0.000758	CcSEcCtD
Sulindac—Pruritus—Conjugated Estrogens—osteoporosis	0.000163	0.000755	CcSEcCtD
Sulindac—Dyspepsia—Estradiol—osteoporosis	0.000162	0.000752	CcSEcCtD
Sulindac—Decreased appetite—Estradiol—osteoporosis	0.00016	0.000743	CcSEcCtD
Sulindac—Fatigue—Estradiol—osteoporosis	0.000159	0.000737	CcSEcCtD
Sulindac—Dizziness—Zoledronate—osteoporosis	0.000158	0.000733	CcSEcCtD
Sulindac—Constipation—Estradiol—osteoporosis	0.000158	0.000731	CcSEcCtD
Sulindac—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000158	0.00073	CcSEcCtD
Sulindac—Nausea—Pamidronate—osteoporosis	0.000156	0.000721	CcSEcCtD
Sulindac—Dizziness—Conjugated Estrogens—osteoporosis	0.000152	0.000706	CcSEcCtD
Sulindac—Vomiting—Zoledronate—osteoporosis	0.000152	0.000705	CcSEcCtD
Sulindac—Feeling abnormal—Estradiol—osteoporosis	0.000152	0.000704	CcSEcCtD
Sulindac—Rash—Zoledronate—osteoporosis	0.000151	0.000699	CcSEcCtD
Sulindac—Gastrointestinal pain—Estradiol—osteoporosis	0.000151	0.000699	CcSEcCtD
Sulindac—Dermatitis—Zoledronate—osteoporosis	0.000151	0.000698	CcSEcCtD
Sulindac—Headache—Zoledronate—osteoporosis	0.00015	0.000695	CcSEcCtD
Sulindac—Vomiting—Conjugated Estrogens—osteoporosis	0.000147	0.000679	CcSEcCtD
Sulindac—Urticaria—Estradiol—osteoporosis	0.000147	0.000679	CcSEcCtD
Sulindac—Body temperature increased—Estradiol—osteoporosis	0.000146	0.000675	CcSEcCtD
Sulindac—Rash—Conjugated Estrogens—osteoporosis	0.000145	0.000673	CcSEcCtD
Sulindac—Dermatitis—Conjugated Estrogens—osteoporosis	0.000145	0.000672	CcSEcCtD
Sulindac—Headache—Conjugated Estrogens—osteoporosis	0.000144	0.000669	CcSEcCtD
Sulindac—Nausea—Zoledronate—osteoporosis	0.000142	0.000659	CcSEcCtD
Sulindac—Nausea—Conjugated Estrogens—osteoporosis	0.000137	0.000634	CcSEcCtD
Sulindac—Hypersensitivity—Estradiol—osteoporosis	0.000136	0.000629	CcSEcCtD
Sulindac—Asthenia—Estradiol—osteoporosis	0.000132	0.000613	CcSEcCtD
Sulindac—Pruritus—Estradiol—osteoporosis	0.00013	0.000604	CcSEcCtD
Sulindac—Diarrhoea—Estradiol—osteoporosis	0.000126	0.000585	CcSEcCtD
Sulindac—Dizziness—Estradiol—osteoporosis	0.000122	0.000565	CcSEcCtD
Sulindac—Vomiting—Estradiol—osteoporosis	0.000117	0.000543	CcSEcCtD
Sulindac—Rash—Estradiol—osteoporosis	0.000116	0.000539	CcSEcCtD
Sulindac—Dermatitis—Estradiol—osteoporosis	0.000116	0.000538	CcSEcCtD
Sulindac—Headache—Estradiol—osteoporosis	0.000116	0.000535	CcSEcCtD
Sulindac—Nausea—Estradiol—osteoporosis	0.00011	0.000507	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB2—IL6—osteoporosis	3.49e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PSMA2—osteoporosis	3.49e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PSMA5—osteoporosis	3.49e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IRS2—osteoporosis	3.47e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—osteoporosis	3.47e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PSMA2—osteoporosis	3.47e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PSMA5—osteoporosis	3.47e-05	0.000187	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—osteoporosis	3.46e-05	0.000186	CbGpPWpGaD
Sulindac—PTGS2—Disease—LRP6—osteoporosis	3.45e-05	0.000186	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TLN1—osteoporosis	3.43e-05	0.000185	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—osteoporosis	3.4e-05	0.000183	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	3.4e-05	0.000183	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—osteoporosis	3.33e-05	0.000179	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PNP—osteoporosis	3.32e-05	0.000179	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ATIC—osteoporosis	3.32e-05	0.000179	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—IDH2—osteoporosis	3.32e-05	0.000179	CbGpPWpGaD
Sulindac—PTGS2—Disease—RPL24—osteoporosis	3.32e-05	0.000179	CbGpPWpGaD
Sulindac—PTGS2—Disease—LTF—osteoporosis	3.32e-05	0.000179	CbGpPWpGaD
Sulindac—ALB—Hemostasis—FGB—osteoporosis	3.31e-05	0.000178	CbGpPWpGaD
Sulindac—ALB—Metabolism—PGLS—osteoporosis	3.31e-05	0.000178	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPD2—osteoporosis	3.31e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO1—osteoporosis	3.27e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—osteoporosis	3.26e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	3.26e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—osteoporosis	3.26e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—osteoporosis	3.23e-05	0.000174	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6R—osteoporosis	3.22e-05	0.000174	CbGpPWpGaD
Sulindac—MAPK3—Disease—PSMA5—osteoporosis	3.22e-05	0.000173	CbGpPWpGaD
Sulindac—MAPK3—Disease—PSMA2—osteoporosis	3.22e-05	0.000173	CbGpPWpGaD
Sulindac—PPARD—Metabolism—MTHFR—osteoporosis	3.22e-05	0.000173	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—osteoporosis	3.21e-05	0.000173	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—osteoporosis	3.19e-05	0.000172	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CA2—osteoporosis	3.18e-05	0.000171	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—OXCT1—osteoporosis	3.18e-05	0.000171	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.15e-05	0.000169	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—osteoporosis	3.14e-05	0.000169	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP27A1—osteoporosis	3.12e-05	0.000168	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IGF1—osteoporosis	3.12e-05	0.000168	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—ESR2—osteoporosis	3.1e-05	0.000167	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MGLL—osteoporosis	3.1e-05	0.000167	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ACP5—osteoporosis	3.03e-05	0.000163	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IRS1—osteoporosis	3.03e-05	0.000163	CbGpPWpGaD
Sulindac—ALB—Metabolism—ATIC—osteoporosis	3.02e-05	0.000163	CbGpPWpGaD
Sulindac—ALB—Metabolism—PNP—osteoporosis	3.02e-05	0.000163	CbGpPWpGaD
Sulindac—MAPK3—Disease—CALCA—osteoporosis	3e-05	0.000162	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—P4HB—osteoporosis	2.96e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KL—osteoporosis	2.95e-05	0.000159	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.92e-05	0.000157	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	2.91e-05	0.000157	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	2.89e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTH—osteoporosis	2.88e-05	0.000155	CbGpPWpGaD
Sulindac—PTGS2—Disease—ACP5—osteoporosis	2.88e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6R—osteoporosis	2.85e-05	0.000153	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RAP1A—osteoporosis	2.83e-05	0.000152	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—OXCT1—osteoporosis	2.82e-05	0.000152	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TPI1—osteoporosis	2.82e-05	0.000152	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CA2—osteoporosis	2.82e-05	0.000152	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—osteoporosis	2.82e-05	0.000152	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CNR2—osteoporosis	2.81e-05	0.000151	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.79e-05	0.00015	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NFATC1—osteoporosis	2.76e-05	0.000149	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MGLL—osteoporosis	2.75e-05	0.000148	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—osteoporosis	2.75e-05	0.000148	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DKK1—osteoporosis	2.74e-05	0.000147	CbGpPWpGaD
Sulindac—MAPK3—Disease—KL—osteoporosis	2.72e-05	0.000147	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—osteoporosis	2.68e-05	0.000145	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.68e-05	0.000144	CbGpPWpGaD
Sulindac—PTGS2—Disease—TPI1—osteoporosis	2.67e-05	0.000144	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—P4HB—osteoporosis	2.65e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—WNT1—osteoporosis	2.64e-05	0.000142	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—IDH2—osteoporosis	2.63e-05	0.000142	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GAPDH—osteoporosis	2.6e-05	0.00014	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.59e-05	0.00014	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—POMC—osteoporosis	2.59e-05	0.000139	CbGpPWpGaD
Sulindac—PPARD—Metabolism—POMC—osteoporosis	2.57e-05	0.000139	CbGpPWpGaD
Sulindac—ALB—Metabolism—OXCT1—osteoporosis	2.57e-05	0.000138	CbGpPWpGaD
Sulindac—ALB—Metabolism—CA2—osteoporosis	2.57e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGA—osteoporosis	2.57e-05	0.000138	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—RAP1A—osteoporosis	2.54e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—ADCY5—osteoporosis	2.53e-05	0.000136	CbGpPWpGaD
Sulindac—PTGS2—Disease—P4HB—osteoporosis	2.51e-05	0.000135	CbGpPWpGaD
Sulindac—ALB—Metabolism—MGLL—osteoporosis	2.51e-05	0.000135	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP27A1—osteoporosis	2.48e-05	0.000133	CbGpPWpGaD
Sulindac—PTGS2—Disease—GAPDH—osteoporosis	2.47e-05	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—VDR—osteoporosis	2.46e-05	0.000132	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FDPS—osteoporosis	2.44e-05	0.000131	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PKM—osteoporosis	2.44e-05	0.000131	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.43e-05	0.000131	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.42e-05	0.000131	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ACP5—osteoporosis	2.41e-05	0.00013	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTHLH—osteoporosis	2.39e-05	0.000128	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BMP2—osteoporosis	2.39e-05	0.000128	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.38e-05	0.000128	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—osteoporosis	2.37e-05	0.000128	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.36e-05	0.000127	CbGpPWpGaD
Sulindac—PTGS2—Disease—NFATC1—osteoporosis	2.34e-05	0.000126	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—IDH2—osteoporosis	2.34e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGB—osteoporosis	2.34e-05	0.000126	CbGpPWpGaD
Sulindac—PTGS2—Disease—DKK1—osteoporosis	2.33e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AGER—osteoporosis	2.32e-05	0.000125	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PGLS—osteoporosis	2.31e-05	0.000125	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPD2—osteoporosis	2.31e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ADCY5—osteoporosis	2.31e-05	0.000124	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.26e-05	0.000122	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—osteoporosis	2.26e-05	0.000122	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PSMA2—osteoporosis	2.25e-05	0.000121	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PSMA5—osteoporosis	2.25e-05	0.000121	CbGpPWpGaD
Sulindac—PTGS2—Disease—WNT1—osteoporosis	2.24e-05	0.000121	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TPI1—osteoporosis	2.24e-05	0.000121	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—osteoporosis	2.22e-05	0.00012	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MYC—osteoporosis	2.21e-05	0.000119	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.21e-05	0.000119	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFB1—osteoporosis	2.21e-05	0.000119	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP27A1—osteoporosis	2.2e-05	0.000118	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGA—osteoporosis	2.18e-05	0.000117	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ACP5—osteoporosis	2.14e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Disease—ADCY5—osteoporosis	2.13e-05	0.000115	CbGpPWpGaD
Sulindac—ALB—Metabolism—IDH2—osteoporosis	2.13e-05	0.000115	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PNP—osteoporosis	2.12e-05	0.000114	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ATIC—osteoporosis	2.12e-05	0.000114	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.11e-05	0.000114	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—P4HB—osteoporosis	2.11e-05	0.000113	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CALCA—osteoporosis	2.1e-05	0.000113	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GAPDH—osteoporosis	2.07e-05	0.000111	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO1—osteoporosis	2.05e-05	0.00011	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRS2—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PSMA2—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PSMA5—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—RAP1A—osteoporosis	2.01e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—osteoporosis	2.01e-05	0.000108	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP27A1—osteoporosis	2e-05	0.000108	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TPI1—osteoporosis	1.99e-05	0.000107	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—osteoporosis	1.98e-05	0.000107	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTHFR—osteoporosis	1.96e-05	0.000106	CbGpPWpGaD
Sulindac—ALB—Metabolism—ACP5—osteoporosis	1.95e-05	0.000105	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO1—osteoporosis	1.94e-05	0.000105	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.92e-05	0.000104	CbGpPWpGaD
Sulindac—PTGS2—Disease—PSMA2—osteoporosis	1.91e-05	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Disease—PSMA5—osteoporosis	1.91e-05	0.000103	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—osteoporosis	1.91e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KL—osteoporosis	1.91e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TGFB1—osteoporosis	1.91e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—ESR1—osteoporosis	1.88e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TGFB1—osteoporosis	1.87e-05	0.000101	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—P4HB—osteoporosis	1.87e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Disease—IRS2—osteoporosis	1.87e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—POMC—osteoporosis	1.86e-05	0.0001	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.84e-05	9.88e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GAPDH—osteoporosis	1.83e-05	9.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6R—osteoporosis	1.81e-05	9.77e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TPI1—osteoporosis	1.81e-05	9.75e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CA2—osteoporosis	1.8e-05	9.68e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—OXCT1—osteoporosis	1.8e-05	9.68e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RAP1A—osteoporosis	1.79e-05	9.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CALCA—osteoporosis	1.78e-05	9.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—osteoporosis	1.78e-05	9.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—osteoporosis	1.77e-05	9.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRS1—osteoporosis	1.77e-05	9.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.76e-05	9.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MGLL—osteoporosis	1.75e-05	9.44e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	1.74e-05	9.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—P4HB—osteoporosis	1.7e-05	9.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GAPDH—osteoporosis	1.67e-05	9e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—osteoporosis	1.66e-05	8.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6R—osteoporosis	1.66e-05	8.93e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.65e-05	8.9e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP19A1—osteoporosis	1.64e-05	8.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IRS1—osteoporosis	1.63e-05	8.78e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RAP1A—osteoporosis	1.63e-05	8.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO1—osteoporosis	1.63e-05	8.76e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KL—osteoporosis	1.62e-05	8.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PSMA2—osteoporosis	1.6e-05	8.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PSMA5—osteoporosis	1.6e-05	8.63e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.56e-05	8.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6R—osteoporosis	1.53e-05	8.24e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IGF1—osteoporosis	1.5e-05	8.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ADCY5—osteoporosis	1.49e-05	8.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—IDH2—osteoporosis	1.49e-05	8.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SPP1—osteoporosis	1.45e-05	7.78e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO1—osteoporosis	1.44e-05	7.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—osteoporosis	1.44e-05	7.73e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PSMA2—osteoporosis	1.42e-05	7.66e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PSMA5—osteoporosis	1.42e-05	7.66e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.42e-05	7.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.4e-05	7.54e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ACP5—osteoporosis	1.36e-05	7.34e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.35e-05	7.25e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ADCY5—osteoporosis	1.34e-05	7.21e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GPX1—osteoporosis	1.33e-05	7.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO1—osteoporosis	1.32e-05	7.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IRS2—osteoporosis	1.31e-05	7.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP19A1—osteoporosis	1.3e-05	7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PSMA2—osteoporosis	1.3e-05	6.98e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PSMA5—osteoporosis	1.3e-05	6.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—LEP—osteoporosis	1.28e-05	6.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ADCY5—osteoporosis	1.27e-05	6.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—osteoporosis	1.27e-05	6.83e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TPI1—osteoporosis	1.27e-05	6.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—osteoporosis	1.26e-05	6.79e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—osteoporosis	1.23e-05	6.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—osteoporosis	1.22e-05	6.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—P4HB—osteoporosis	1.19e-05	6.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GAPDH—osteoporosis	1.17e-05	6.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—osteoporosis	1.17e-05	6.28e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP19A1—osteoporosis	1.15e-05	6.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IRS1—osteoporosis	1.14e-05	6.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RAP1A—osteoporosis	1.14e-05	6.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IRS2—osteoporosis	1.11e-05	5.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—POMC—osteoporosis	1.1e-05	5.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6R—osteoporosis	1.07e-05	5.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ADCY5—osteoporosis	1.06e-05	5.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPX1—osteoporosis	1.06e-05	5.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—osteoporosis	1.06e-05	5.69e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP19A1—osteoporosis	1.05e-05	5.67e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.93e-06	5.35e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—POMC—osteoporosis	9.85e-06	5.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—osteoporosis	9.77e-06	5.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—osteoporosis	9.77e-06	5.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IRS1—osteoporosis	9.69e-06	5.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ADCY5—osteoporosis	9.43e-06	5.08e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPX1—osteoporosis	9.4e-06	5.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO1—osteoporosis	9.21e-06	4.96e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6R—osteoporosis	9.1e-06	4.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—osteoporosis	9.07e-06	4.89e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PSMA2—osteoporosis	9.07e-06	4.88e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PSMA5—osteoporosis	9.07e-06	4.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—osteoporosis	9.05e-06	4.87e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—osteoporosis	8.99e-06	4.84e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—osteoporosis	8.67e-06	4.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ADCY5—osteoporosis	8.6e-06	4.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPX1—osteoporosis	8.57e-06	4.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—osteoporosis	8.08e-06	4.35e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—osteoporosis	7.91e-06	4.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POMC—osteoporosis	7.82e-06	4.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—osteoporosis	7.39e-06	3.98e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP19A1—osteoporosis	7.36e-06	3.96e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POMC—osteoporosis	6.94e-06	3.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—osteoporosis	6.82e-06	3.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—osteoporosis	6.35e-06	3.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—osteoporosis	6.34e-06	3.41e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POMC—osteoporosis	6.32e-06	3.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADCY5—osteoporosis	6.01e-06	3.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPX1—osteoporosis	5.99e-06	3.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—osteoporosis	5.53e-06	2.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—osteoporosis	5.4e-06	2.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—osteoporosis	5.38e-06	2.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—osteoporosis	4.78e-06	2.57e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POMC—osteoporosis	4.42e-06	2.38e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—osteoporosis	4.06e-06	2.18e-05	CbGpPWpGaD
